1. Home
  2. ACRS vs CMCM Comparison

ACRS vs CMCM Comparison

Compare ACRS & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • CMCM
  • Stock Information
  • Founded
  • ACRS 2012
  • CMCM 2009
  • Country
  • ACRS United States
  • CMCM China
  • Employees
  • ACRS N/A
  • CMCM N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • ACRS Health Care
  • CMCM Technology
  • Exchange
  • ACRS Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • ACRS 165.7M
  • CMCM 196.4M
  • IPO Year
  • ACRS 2015
  • CMCM 2014
  • Fundamental
  • Price
  • ACRS $1.93
  • CMCM $8.46
  • Analyst Decision
  • ACRS Strong Buy
  • CMCM
  • Analyst Count
  • ACRS 9
  • CMCM 0
  • Target Price
  • ACRS $9.25
  • CMCM N/A
  • AVG Volume (30 Days)
  • ACRS 800.9K
  • CMCM 87.7K
  • Earning Date
  • ACRS 11-05-2025
  • CMCM 09-11-2025
  • Dividend Yield
  • ACRS N/A
  • CMCM N/A
  • EPS Growth
  • ACRS N/A
  • CMCM N/A
  • EPS
  • ACRS N/A
  • CMCM N/A
  • Revenue
  • ACRS $16,789,000.00
  • CMCM $137,272,956.00
  • Revenue This Year
  • ACRS N/A
  • CMCM $14.27
  • Revenue Next Year
  • ACRS N/A
  • CMCM $39.26
  • P/E Ratio
  • ACRS N/A
  • CMCM N/A
  • Revenue Growth
  • ACRS N/A
  • CMCM 38.54
  • 52 Week Low
  • ACRS $1.05
  • CMCM $3.28
  • 52 Week High
  • ACRS $5.17
  • CMCM $9.39
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 54.35
  • CMCM 68.35
  • Support Level
  • ACRS $1.81
  • CMCM $7.76
  • Resistance Level
  • ACRS $2.16
  • CMCM $9.39
  • Average True Range (ATR)
  • ACRS 0.12
  • CMCM 0.65
  • MACD
  • ACRS -0.03
  • CMCM 0.18
  • Stochastic Oscillator
  • ACRS 34.29
  • CMCM 75.59

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: